The TCGA pancancer study also teaches us that the proportion of tumors with mutated CDKN2A with respect to deletions is among the highest in pancreatic cancer (together with bladder cancer, non-small cell lung cancer, melanoma) (Figure 6). The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.